Area of research
Rheumatology · Hematology
Research interest
Research interests include Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Spondyloarthritis Studies and Treatments, and Autoimmune and Inflammatory Disorders Research.
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice
The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
Validation of new classification criteria of rheumatoid arthritis in an international multicentre study.
PubMed 2020cited by 3position: middle
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial